Anaphylaxis Treatment Market

SKU: DMPH2876 | Last Updated On: Aug 03 2022 | Available Formats

> Global Anaphylaxis Treatment Market Expected to reach a high CAGR 8.2% during the forecast period 2022-2029: DataM Intelligence

Anaphylaxis Treatment Market is segmented By Drug Class (Adrenergic Agonists, Antihistamines (Diphenhydramine (Benadryl), Hydroxyzine (Vistaril)), H2 Receptor Antagonists (Cimetidine (Tagamet), Ranitidine (Zantac), Famotidine (Pepcid)), Bronchodilators (Albuterol (Proventil HFA, Ventolin HFA, ProAir HFA)), Corticosteroids (Methylprednisolone (Solu-Medrol), Prednisone), Positive Inotropic Agents (Glucagon (GlucaGen)), Vasopressors (Dopamine (Intropin)), By Route of Administration (Parenteral, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Anaphylaxis Treatment Market Size Volume Growth Insights

The Global Anaphylaxis Treatment Market is expected to grow at a high CAGR of 8.2% during the forecasting period (2022-2029). Anaphylaxis is a severe allergic reaction to the venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Some of the common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex.

The primary drug treatments for acute anaphylactic reactions are epinephrine and H1 antihistamines. As per the 2013 World Allergy Association update, 2015 Joint Task Force anaphylaxis update, and 2010 NIAID guidelines, epinephrine is the drug of choice for life-threatening reactions.

Market Dynamics

The global anaphylaxis treatment Market growth is driven by several factors such growing prevalence of allergies and their awareness among customers, and increasing advancement in the product with cost-effective solutions.      

Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.

The rise in patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. In the US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.

As per a journal published on NCBI (National Center for Biotechnology Information) in 2017, up to 5% of the U.S. population suffered from the anaphylaxis condition. In addition, around 1% of total hospitalizations and 0.1% of emergency attendances for anaphylaxis would have fatal outcomes. Drugs are a major cause of fatal anaphylaxis in various countries, such as Australia, New Zealand, the U.K., Brazil, and the U.S. As per a journal published on NCBI, in the year 2018, the lifetime prevalence of anaphylaxis is estimated to be 0.05% – 2% in the U.S., and approx. 3% in Europe. Overall, the fatality of anaphylaxis conditions is relatively low across the globe.

Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of the anaphylaxis treatment market.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person, due to the fear of spreading coronavirus (COVID-19). Thus, companies in the anaphylaxis treatment market are adopting telemedicine as individuals prefer remote healthcare services amidst the COVID-19 era. The demand for telehealth technology is expected to rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics.

Anaphylaxis Treatment Market Scope

Metrics

Details

Market CAGR

8.%

Segments Covered

 By Drug Class, By Route of Administration, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Segment Analysis

The global anaphylaxis treatment Market is segmented into dosage, age-group, and end-user.

By Drug Class, Adrenergic Agonists held the Largest Share in the Global Anaphylaxis Treatment Market.

  • Adrenergic Agonists: These agents help maintain blood pressure, antagonize effects of released mediators, and prevent further release of mediators.
    • Epinephrine (Adrenaline, EpiPen, EpiPen Jr, Twinject, Adrenaclick): Epinephrine is the drug of choice for treating anaphylaxis.
  • Antihistamines: Antihistamines are primarily effective against cutaneous effects of anaphylaxis. Also may help antagonize cardiac and respiratory effects; should be used routinely in most cases of anaphylaxis. IV administration is preferable when a rapid effect is desired. IM dosing also is effective but has a slower onset than IV and may cause local tissue irritation.
    • Diphenhydramine (Benadryl): Diphenhydramine has a long history of efficacy and relative safety. It has an FDA indication for anaphylaxis. IV administration provides faster onset of action.
    • Hydroxyzine (Vistaril): Hydroxyzine is an H1 antihistamine. It may suppress histamine activity in the subcortical region of the CNS.
  • H2 Receptor Antagonists: These agents block effects of released histamine at H2 receptors, thereby treating vasodilation, possibly some cardiac effects, and glandular hypersecretion. H2 blockers with H1 blockers have the additive benefit over H1 blockers alone in treating anaphylaxis. Ranitidine (Zantac) is probably preferred over cimetidine (Tagamet) in anaphylaxis in light of the risk for hypotension with rapidly infused cimetidine and the multiple, complex drug interactions with cimetidine. Famotidine (Pepcid) IV is another good alternative.
    • Cimetidine (Tagamet): Many H2 blockers are available. Cimetidine is the prototype drug; other agents have much less evidence of effectiveness in anaphylaxis.
    • Ranitidine (Zantac): Ranitidine is an H2 antagonist, which, when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.
    • Famotidine (Pepcid): H2 antagonist that when combined with an H1 type, may be useful in treating allergic reactions that do not respond to H1 antagonists alone.
  • Bronchodilators: These agents stimulate beta2-adrenergic receptors in bronchial smooth muscle, causing bronchodilation. Inhaled beta-agonists are used to counteract bronchospasm and should be administered to patients who are wheezing.
    • Albuterol (Proventil HFA, Ventolin HFA, ProAir HFA): Albuterol is a beta-agonist for bronchospasm refractory to epinephrine. It relaxes bronchial smooth muscle by action on beta2-receptors, with little effect on cardiac muscle contractility.
  • Corticosteroids: Corticosteroids have a delayed onset of action and do not reverse the cardiovascular effects of anaphylaxis. These agents should be used in severe reactions, but the use of epinephrine and H1 antihistamines has a higher priority.
    • Methylprednisolone (Solu-Medrol): Methylprednisolone may help prevent late-phase allergic reactions (biphasic anaphylaxis). It has no immediate effects.
    • Prednisone: Prednisone is an immunosuppressant for the treatment of allergic reactions. It may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
  • Positive Inotropic Agents: These agents help maintain blood pressure independent of adrenergic receptors by increasing intracellular levels of cyclic AMP. In addition, stimulate the release of endogenous catecholamines.
    • Glucagon (GlucaGen): Glucagon might be beneficial for severe anaphylaxis in patients taking beta-blockers, although data are limited to case reports.
  • Vasopressors: These agents are useful as adjunctive therapy to IV fluids to treat refractory hypotension from anaphylaxis.
    • Dopamine (Intropin): Dopamine often is considered the drug of choice for anaphylaxis-induced refractory hypotension. It stimulates both adrenergic and dopaminergic receptors.

Geographical Analysis

In terms of region, the global anaphylaxis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is Expected to Dominate the Global Anaphylaxis Treatment Market

North America accounted for the largest market share of the global anaphylaxis treatment Market in 2019, owing to the rise in the patient pool suffering from the condition. In addition, awareness of the allergic tests and fatalities due to various allergic conditions are projected to boost the growth of the anaphylaxis treatment market in this region.  Also, lifestyle changes, early diagnosis of specific allergies, and availability of anaphylaxis treatment are likely to boost the expansion of the anaphylaxis treatment market in North America. Some of the key players in the region are focusing on launching innovative products, including the generic version of epinephrine, for the anaphylaxis condition. This is projected to fuel market growth in the region. 

Competitive Landscape

Some of the major players in the global anaphylaxis treatment market include ALK-Abelló A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anaphylaxis treatment market globally. For instance,

  • Teva Pharmaceutical Industries Ltd has developed an EpiPen which is a generic version of EpiPen Jr and approved by the FDA in August 2019. The pen is developed using VIBEX device by Antares Pharma to prevent and provide aid against life-threatening, allergic emergencies including anaphylaxis or any allergic history in genes of the patient. The dose of the EpiPen depends on the weight and fitness of the patient or as prescribed by the medical practitioners.
  • In June 2017, The FDA approved an epinephrine injector product called Symjepi, made by Adamis Pharmaceutical Corp. as the latest alternative to Mylan Pharmaceuticals' EpiPen for the treatment of severe allergic reactions. The product is a 0.3-mg prefilled syringe for the emergency treatment of allergic reactions, including anaphylaxis, for patients who weigh 30 kg (66 pounds) or more.
  • In July 2018, INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis.

Pfizer Inc.

Overview:

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

Products:

  • EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors

Key Developments:

  • In April 2012, Mylan Inc. and Pfizer Inc. announced that Meridian Medical Technologies, a Pfizer subsidiary, has entered into a settlement agreement with Teva that will resolve pending patent litigation related to its abbreviated new drug application (ANDA) for a generic epinephrine auto-injector.

Trending Topics

Healthcare Virtual Assistant Market

Disposable Spinal Instruments Market

Cranial Implant Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest